These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14574520)

  • 1. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.
    Prod'homme T; Dekel B; Barbieri G; Lisowska-Grospierre B; Katz R; Charron D; Alcaide-Loridan C; Pollack S
    Immunogenetics; 2003 Nov; 55(8):530-9. PubMed ID: 14574520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency.
    Lennon-Duménil AM; Barbouche MR; Vedrenne J; Prod'Homme T; Béjaoui M; Ghariani S; Charron D; Fellous M; Dellagi K; Alcaïde-Loridan C
    J Immunol; 2001 May; 166(9):5681-7. PubMed ID: 11313409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Immunological, and Molecular Findings in Five Patients with Major Histocompatibility Complex Class II Deficiency from India.
    Aluri J; Gupta M; Dalvi A; Mhatre S; Kulkarni M; Hule G; Desai M; Shah N; Taur P; Vedam R; Madkaikar M
    Front Immunol; 2018; 9():188. PubMed ID: 29527204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined immunodeficiency with defective expression in MHC class II genes.
    Griscelli C; Lisowska-Grospierre B; Mach B
    Immunodefic Rev; 1989; 1(2):135-53. PubMed ID: 2517209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation in the class II trans-activator leading to a mild immunodeficiency.
    Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
    J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Steimle V; Otten LA; Zufferey M; Mach B
    Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
    Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
    Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
    Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
    Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II deficiency: Report of a novel mutation and special review.
    Farrokhi S; Shabani M; Aryan Z; Zoghi S; Krolo A; Boztug K; Rezaei N
    Allergol Immunopathol (Madr); 2018; 46(3):263-275. PubMed ID: 28676232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-II Deficiency Among Egyptians: Novel Mutations and Unique Phenotypes.
    El Hawary RE; Mauracher AA; Meshaal SS; Eldash A; Abd Elaziz DS; Alkady R; Lotfy S; Opitz L; Galal NM; Boutros JA; Pachlopnik Schmid J; Elmarsafy AM
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):856-863. PubMed ID: 30170160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
    Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
    Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
    Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
    Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency.
    Matheux F; Ikinciogullari A; Zapata DA; Barras E; Zufferey M; Dogu F; Regueiro JR; Reith W; Villard J
    Mol Ther; 2002 Dec; 6(6):824-9. PubMed ID: 12498778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC Class II Deficiency: Clinical, Immunological, and Genetic Insights in a Large Multicenter Cohort.
    Gulec Koksal Z; Bilgic Eltan S; Topyildiz E; Sezer A; Keles S; Celebi Celik F; Ozhan Kont A; Gemici Karaaslan B; Sefer AP; Karali Z; Arik E; Ozek Yucel E; Akcal O; Karakurt LT; Yorgun Altunbas M; Yalcin K; Uygun V; Ozek G; Babayeva R; Aydogmus C; Ozcan D; Cavkaytar O; Keskin O; Kilic SS; Kiykim A; Arikoglu T; Genel F; Gulez N; Guner SN; Karaca NE; Reisli I; Kutukculer N; Altintas DU; Ozen A; Karakoc Aydiner E; Baris S
    J Allergy Clin Immunol Pract; 2024 Sep; 12(9):2490-2502.e6. PubMed ID: 38996837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population.
    Naamane H; El Maataoui O; Ailal F; Barakat A; Bennani S; Najib J; Hassar M; Saile R; Bousfiha AA
    Eur J Pediatr; 2010 Sep; 169(9):1069-74. PubMed ID: 20414676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class I and II deficiencies.
    Hanna S; Etzioni A
    J Allergy Clin Immunol; 2014 Aug; 134(2):269-75. PubMed ID: 25001848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B.
    Wiszniewski W; Fondaneche MC; Lambert N; Masternak K; Picard C; Notarangelo L; Schwartz K; Bal J; Reith W; Alcaide C; de Saint Basile G; Fischer A; Lisowska-Grospierre B
    Immunogenetics; 2000 Apr; 51(4-5):261-7. PubMed ID: 10803838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency.
    Villard J; Lisowska-Grospierre B; van den Elsen P; Fischer A; Reith W; Mach B
    N Engl J Med; 1997 Sep; 337(11):748-53. PubMed ID: 9287230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X.
    Reith W; Satola S; Sanchez CH; Amaldi I; Lisowska-Grospierre B; Griscelli C; Hadam MR; Mach B
    Cell; 1988 Jun; 53(6):897-906. PubMed ID: 3133120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene.
    Peijnenburg A; Van Eggermond MC; Van den Berg R; Sanal O; Vossen JM; Van den Elsen PJ
    Immunogenetics; 1999 Apr; 49(4):338-45. PubMed ID: 10079298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.